Speak at the EuroMeeting 2014

 

26th Annual EuroMeeting 2014
March 25-27 | Vienna, Austria
Abstract submission deadline: May 29

Submit your presentation, session or tutorial abstracts for DIA’s Annual EuroMeeting and share your research with more than 3,000 professionals from around the world.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and manage the session. PowerPoint presentations are required. We welcome innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area. The abstract author is considered the speaker and a PowerPoint presentation is required.

Tutorial Abstract
A tutorial is a ‘hands-on’, interactive learning experience. A tutorial consists of three hours of instruction with a 30-minute break halfway through. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organization as the author.

To give your session, presentation or tutorial abstract the best chance of being accepted focus on the programme themes.

Hot-Topic/Stand-Alone Sessions
Each year, there are a number of sessions that do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes/topics outlined, you may submit it for consideration as a hot-topic/stand-alone presentation/session.

Find Out More | Submit Your Abstract

Sign up for DIA's Global SmartBrief: Break through the information clutter with FREE, twice-weekly email publication that gives quick, easy-to-read summaries of articles relevant to you. Get the latest news in drug development innovations worldwide wherever you are on your laptop or smart phone with SmartBrief’s wireless compatibility.

PDUFA V Statistical Topics and Emerging New Issues

Call for Posters and Roundtable Luncheon Topics Deadlines Extended This year’s theme is PDUFA V Statistical Topics and Emerging New Issues. Now in its seventh year, this unique forum continues the dialogue on issues including FDA guidance development and regulatory science initiatives including PDUFA V initiatives, as well as statistical opportunities and challenges associated with data standards and innovative approaches to the design, monitoring, analysis, and reporting of clinical trials and assessments of safety and effectiveness in the pre- and post-market settings. Over the three days, in-depth discussions on key topics relevant to the evaluation of therapeutic products will take place, and include input from key thought leaders from regulatory agencies, industry, and academia. With the success of last year’s forum we will continue to offer additional avenues for interaction and scientific discourse via a scientific poster session during the networking reception and an interactive round-table luncheon event. Call for Posters Submission Deadline: February 28 Call for Roundtable Luncheon Topics Submission Deadline: February 28 Please Note: DIA User ID and Password is needed to submit an abstract. Did you land on the My DIA Page? If so, please select “My Abstract Submissions” on the left side to submit an abstract. Overview | Agenda | Register Online Keynote Speaker: Monday, April 29 Robert N. Rodriguez, PhD Past President, American Statistical Association Senior Director, Statistical Research and Development SAS Institute Session Topics: • PDUFA V Overview • Statisticians as Leaders • FDA Upcoming Guidance Update (Multiplicity and Enriched Populations) • Dichotomizing Continuous Measures for a Primary Efficacy Endpoint – Weighing the Benefits and Risks • Measures for Primary Efficacy Endpoint – Are we Substantially Compromising Statistical Power? • Pre-Competitive Collaboration • Meta Analysis for Safety Data • Companion Diagnostics • (Premarketing) Benefit-Risk Assessment in Clinical Development and Regulatory Review • (Premarketing) Benefit-Risk Assessments • Health Technology Assessment and Comparative Effectiveness Research: Their Impact on Access to Pharmaceutical Products and Their Role in Designing Product Development Strategies • Missing Data: When is it Important to Collect Data After Study Drug Discontinuation? • Missing Data: Case Study Presentation and Panel Discussion • Overview and Commentary of FDA Guidances: Multiplicity and/or Enriched Populations Tutorial Topics: • Statistical Methods for Safety Surveillance • Missing Data in Clinical Trials • Benefit-Risk Evaluation We look forward to seeing you in April! Regards, Constance Burnett Content Lead Constance.Burnett@diahome.org We think you might also like these... Introduction to Signal Detection and Data Mining Global Considerations for Regulatory Strategy Development DIA/FDA Industry PDUFA V Conference Unwrapping FDA’s 2012 UFA Package: What’s Inside the Statute, What’s Next?

Email Preferences | My DIA | Forward to a Friend |